iCell Gene Therapeutics is at the forefront of developing innovative cell therapies aimed at addressing unmet medical needs in autoimmune diseases and cancer. The company specializes in chimeric antigen receptor (CAR) engineered cell therapies, particularly targeting B cell-mediated autoimmune conditions such as systemic lupus erythematosus and various cancers, including acute myeloid leukemia. Their proprietary compound CAR (cCAR) technology is designed to effectively deplete memory B cells and plasma cells, thereby resetting the humoral immune system. This approach has shown promising clinical outcomes, with patients achieving medication-free remission for extended periods. Additionally, iCell's cCAR technology targets specific surface antigens like CD19 and BCMA, ensuring high precision and safety in treatment.

In the realm of oncology, iCell is advancing its cCAR technology to combat acute myeloid leukemia by targeting malignant cells with precision, focusing on antigens such as CD33 and CLL-1. The company also employs Super NK cell technology to treat solid tumors, which enhances patient access through its off-the-shelf capabilities. Furthermore, iCell's non-gene editing CAR T-cell constructs are designed to target T-cell malignancies with a streamlined approach that maximizes patient safety while maintaining effective cytotoxicity. With seven of their CAR therapies receiving Orphan Drug Designation from the FDA, iCell is committed to developing cost-effective and innovative treatments for serious conditions with significant unmet needs.

United States

iCell Gene Therapeutics is developing Chimeric Antigen Receptor (CAR) engineered cells with improved functional properties and expanded applicability. We are a clinical stage company focused to demonstrate clinical proof of concept for unique, patent protected, targets and strategies.

Our pipeline includes multiple additional first in man CAR strategies to target hematological cancers, non-hematological cancers and autoimmune disorders.

iCell Gene Therapeutics

Company Details